TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 09/11/23

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 12 1 − Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study of TAK-279 ...

2023-08-31 17:58:28 ET Summary Takeda Pharmaceutical has recorded a 16.79% total return over the last 50 weeks, but risks are piling up, including loss of exclusivity and a sizable debt load. The advent of biosimilars for Takeda's major pharmaceuticals, Velcade and Vyvanse, will s...

2023-08-31 11:17:22 ET Summary Novo Nordisk is a high-quality pharmaceutical company with a unique ownership structure, controlled by a charitable foundation. The company specializes in diabetes and obesity treatments, with a focus on insulin and GLP-1 analogues. Despite a tem...

2023-08-29 13:45:03 ET Summary Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as ...

2023-08-28 07:12:00 ET More on ImmunoGen, Takeda, etc. ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ELAHERE Has Likely Blockbuster Potential ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential Takeda: Upside Ca...

2023-08-24 17:00:00 ET If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS) . Both companies offer attractive dividends, but which one is a better buy...

2023-08-23 14:22:14 ET Dividend stocks can be a port in the storm. Thanks to powerful wealth-building vehicles like dividend reinvestment plans, these stocks can take advantage of the power of both dollar-cost averaging and compounding. However, not all dividend stocks are great buys. Compa...

2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-07-31 09:00:00 ET Summary ASKA Pharmaceuticals' market cap is covered 30% by net non-operating assets that render its EV/EBITDA multiple too low for a growing generics business in Japan. It has a growing exposure to gynecological drugs, which in some cases are receiving benef...